FI82460B - Foerfarande foer framstaellning av nya, -adrenergiskt blockerande 2,2'-iminobisetanolderivat. - Google Patents
Foerfarande foer framstaellning av nya, -adrenergiskt blockerande 2,2'-iminobisetanolderivat. Download PDFInfo
- Publication number
- FI82460B FI82460B FI844777A FI844777A FI82460B FI 82460 B FI82460 B FI 82460B FI 844777 A FI844777 A FI 844777A FI 844777 A FI844777 A FI 844777A FI 82460 B FI82460 B FI 82460B
- Authority
- FI
- Finland
- Prior art keywords
- parts
- formula
- dihydro
- benzopyran
- iii
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (11)
1. Förfarande för framställning av nya, β-adrener-giskt blockerande 2,2’-iminobisetanolderivat med formeln 5 I «10 r6or2 r1 r3o H7 f14 “ - r13 H R17 15 eller farmaceutuiskt godtagbara syraadditionssalter eller stereokemiskt isomeriska former därav, i vilken formel R1 är väte, C1.4-alkyl, fenylmetyl eller C^-alkyl-karbonyl;
20 R2 och R3 är bäda självständigt väte eller Cj^-al- kylkarbonyl; R4, R5, R6 och R7 är vardera självständigt väte eller C^-alkyl; A1 och A2 är bäda självständigt en direkt bindning 25 eller -CH2-; och R10, R11, R12, R13, R14, R15, R16 och R17 är vardera självständigt väte, halogen, C^-alkyl, Cl.4-alkyloxi, C2_ 6-alkenylmetoxi, hydroxi, cyan, fenylmetyloxi eller en grupp med formeln (a) 30 -(NH)p-X-(0)q-L (a) väri p och q är själständigt 0 eller heltalet 1; X är >00 eller -S(=0)2-; och L är C1.4-alkyl; eller ... 35 tvä närliggande grupper av grupperna R10, R11, R12 och R13 samt av grupperna R14, R15, R16 och R17 kan bilda en so 8 2 460 bivalent grupp som är -CH=CH-CH=CH- eller -(CH2)4-; under förutsättning att högst tvä grupper av grupperna R10, R11, R12 och R13 eller av grupperna R14, R15, R16 och R17 är en grupp med formeln (a); 5 kännetecknat därav, att man
1. N-alkylerar en amin med formeln Il-a OR2 1 1 D1-C-CH2-NH-R1 ( I i -a)
10 R4 med en reagens med formeln Ill-a 15 <j)R3 w-CH,-C-D2 (m-a) 2 l5 R5 i ett lämpligt, reaktionsinert medium; eller 20 2) N-alkylerar en amin med formeln Il-b OR3 D2-C-CH2-NH-R1 ( ΙΙ-b ) R5 ·: 25 med en reagens med formeln Ill-b OR2 , I D-C-CH2-W (Ill-b)
30 R4 ett lämpligt, reaktionsinert medium; eller
3. N-alkylerar en amin med formeln Il-a OR2
35 D1-C-CH2-NH-R1 (Il-a) R4 51 82460 med ett oxiran med formeln III-a-1 /°\ 2 H,C - C-D2 (III-a-1) 5 if i ett lämpligt, reaktionsinert medium, för att framställa en förening med formeln (I) väri R3 är väte; eller
4. N-alkylerar en amin med formeln Il-b 10 OR3 D2-i-CH2-NH-R1 (11 -b) R5 15 med ett oxiran med formeln III-b-1 /°\ H2C--C-D1 (III-b-1)
20 R4 i ett lämpligt, reaktionsinert medium, för att framställa en förening med formeln (I) väri R2 är väte; och 25 ifall önskvärt, omvandlar föreningarna med formenl (I) till form av ett terapeutiskt aktivt, giftfritt syra-additiossalt genom behandling med en lämplig syra, eller omvänt, omvandlar syraadditiossaltet till fri basform med alkali; och/eller framställer stereokemiskt isomeriska 30 former därav, i vilka formler Dl betecknar en grupp med formeln '•'f. *10 6 R11 [ „ R
35 VV°\·- R^krAA1"\ A13 H 52 82460 D2 betecknar en grupp med formeln
7 R14 5 \/°xJL-R15 I17 10 och W betecknar en lämplig, reaktiv avgäende grupp, säsom exempelvis halogen, t.ex. klor, brom eller jod, eller sulfonyloxigrupp, t.ex. metylsulfonyloxi eller 4-metylfe-nylsulfonyloxi. 15 2. Förfarande enligt patentkravet 1 för framställ- ning av α,α'-[iminobis(metylen)]bis(3,4-dihydro-2H-l-ben-sopyran-2-metanol], ett farmaceutiskt godtagbart syraad-ditionssalt därav eller en stereokemiskt isomerisk form därav. 20 II
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55808183A | 1983-12-05 | 1983-12-05 | |
| US55808183 | 1983-12-05 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI844777A0 FI844777A0 (fi) | 1984-12-04 |
| FI844777L FI844777L (fi) | 1985-06-06 |
| FI82460B true FI82460B (fi) | 1990-11-30 |
| FI82460C FI82460C (sv) | 1991-03-11 |
Family
ID=24228139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI844777A FI82460C (sv) | 1983-12-05 | 1984-12-04 | Förfarande för framställning av nya, -adrenergiskt blockerande 2,2'-i minobisetanolderivat |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP0145067B1 (sv) |
| JP (1) | JPS60132977A (sv) |
| KR (1) | KR870000923B1 (sv) |
| AR (1) | AR241414A1 (sv) |
| AT (1) | ATE40361T1 (sv) |
| AU (1) | AU573658B2 (sv) |
| BG (1) | BG43866A3 (sv) |
| CA (1) | CA1337429C (sv) |
| CS (1) | CS250242B2 (sv) |
| CY (1) | CY1609A (sv) |
| DD (1) | DD235453A5 (sv) |
| DE (1) | DE3476388D1 (sv) |
| DK (2) | DK165112C (sv) |
| DZ (1) | DZ712A1 (sv) |
| ES (1) | ES538256A0 (sv) |
| FI (1) | FI82460C (sv) |
| GR (1) | GR81098B (sv) |
| HK (1) | HK52791A (sv) |
| HU (1) | HU202219B (sv) |
| IE (1) | IE57831B1 (sv) |
| IL (1) | IL73706A (sv) |
| MA (1) | MA20292A1 (sv) |
| NO (2) | NO169839C (sv) |
| NZ (1) | NZ210388A (sv) |
| PH (1) | PH22432A (sv) |
| PL (1) | PL146342B1 (sv) |
| PT (1) | PT79609B (sv) |
| RO (1) | RO91184B (sv) |
| SG (1) | SG47091G (sv) |
| SU (1) | SU1428199A3 (sv) |
| ZA (1) | ZA849445B (sv) |
| ZW (1) | ZW19784A1 (sv) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1337432C (en) * | 1988-03-23 | 1995-10-24 | Raymond M. Xhonneux | Method of lowering the blood pressure |
| JPH02103116U (sv) * | 1989-02-01 | 1990-08-16 | ||
| JPH02218675A (ja) * | 1989-02-21 | 1990-08-31 | Nippon Kayaku Co Ltd | ６―フルオロクロモン―２―カルボン酸及びその製造法 |
| TW199152B (sv) * | 1990-11-01 | 1993-02-01 | Takeda Pharm Industry Co Ltd | |
| TW355683B (en) * | 1994-02-17 | 1999-04-11 | Janssen Pharmaceutica Nv | Composition containing micronized nebivolol |
| ATE210657T1 (de) * | 1994-10-14 | 2001-12-15 | Merck Patent Gmbh | Zns wirksames (r)-(-)-2-(5-(4-fluorophenyl)-3- pyridylmethylaminomethyl)chroman |
| RU2223269C2 (ru) * | 1997-12-19 | 2004-02-10 | Байер Корпорейшн | Производные хромана, промежуточные соединения, фармацевтическая композиция и способы лечения. |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| US6713651B1 (en) | 1999-06-07 | 2004-03-30 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6593497B1 (en) | 1999-06-02 | 2003-07-15 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| UA73965C2 (en) | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| UA73981C2 (en) | 2000-03-10 | 2005-10-17 | Merck Patent Gmbh | (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit |
| ATE437637T1 (de) | 2001-05-02 | 2009-08-15 | Nitromed Inc | Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren |
| JP2004538289A (ja) | 2001-07-26 | 2004-12-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ２−［５−（４−フルオロフェニル）−３−ピリジルメチルアミノメチル］−クロマンおよびその生理学的に許容し得る塩の新規な使用 |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
| US8604222B2 (en) * | 2004-07-30 | 2013-12-10 | Forest Laboratories Holdings Limited | Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol |
| ES2341250T3 (es) * | 2004-08-11 | 2010-06-17 | Hetero Drugs Limited | Procedimiento novedoso de preparacion de intermediarios de nebivolol. |
| CN100341866C (zh) * | 2004-08-30 | 2007-10-10 | 中国科学院理化技术研究所 | α，α’－[亚氨基二（亚甲基）]－双－（6－氟－3，4－二氢－2H－1－苯并吡喃－2－甲醇）甲烷磺酸盐的合成方法 |
| NZ560386A (en) | 2005-01-31 | 2009-12-24 | Mylan Lab Inc | Pharmaceutical composition comprising hydroxylated nebivolol |
| WO2006084684A1 (de) * | 2005-02-11 | 2006-08-17 | Stada Arzneimittel Ag | Pharmazeutische zusammensetzungen nebivolo und ein hydrophiles polymer |
| AT502220A1 (de) * | 2005-07-19 | 2007-02-15 | Pharmacon Forschung & Beratung | Verfahren zur herstellung von nebivolol |
| US7560575B2 (en) | 2005-12-28 | 2009-07-14 | Acino Pharma Ag | Process for preparation of racemic Nebivolol |
| EP1803716B1 (en) * | 2005-12-28 | 2012-07-25 | Acino Pharma AG | A process for preparation of racemic nebivolol |
| WO2007083318A1 (en) | 2006-01-18 | 2007-07-26 | Hetero Drugs Limited | Process for isolation of desired isomers of nebivolol intermediates |
| ITMI20061889A1 (it) * | 2006-10-03 | 2008-04-04 | Zambon Spa | Processo di preparazione di nebivololo |
| ES2426399T3 (es) | 2006-11-27 | 2013-10-23 | Zach System S.P.A. | Formiato de nebivolol |
| CA2675538C (en) | 2007-01-22 | 2017-02-28 | Genpharm Ulc | Oral pharmaceutical compositions comprising unmicronized nebivolol or a nebivolol analogue as active ingredient, and a decreased ratio of wetting agent to active ingredient |
| CN101463024B (zh) | 2007-12-21 | 2011-06-08 | 上海现代制药股份有限公司 | 一种制备rrrs和sssr型的奈必洛尔中间体混合物的方法 |
| ITMI20080547A1 (it) * | 2008-03-31 | 2009-10-01 | Zach System Spa | Processo di preparazione di nebivololo |
| IT1392067B1 (it) * | 2008-10-31 | 2012-02-09 | Zach System Spa | Processo di preparazione di nebivololo |
| IT1395354B1 (it) * | 2009-07-23 | 2012-09-14 | Zach System Spa | Processo di preparazione di nebivololo |
| DE102010005953A1 (de) | 2010-01-27 | 2011-07-28 | Corden PharmaChem GmbH, 68305 | Verfahren zur Herstellung von Nebivolol |
| IT1397962B1 (it) | 2010-02-11 | 2013-02-04 | Menarini Int Operations Lu Sa | Processo per la preparazione del nebivololo. |
| IT1402974B1 (it) | 2010-11-30 | 2013-09-27 | Menarini Int Operations Lu Sa | Processo per la preparazione del nebivololo. |
| ITRM20110418A1 (it) | 2011-08-02 | 2013-02-03 | Menarini Int Operations Lu Sa | Processo per la preparazione di epossidi quali intermedi per la sintesi del nebivololo. |
| EP2907809B1 (en) | 2014-02-14 | 2018-08-22 | Corden Pharma International GmbH | Base-free process for the preparation of ketone intermediates usable for manufacture of nebivolol |
| EP2907810A1 (en) | 2014-02-14 | 2015-08-19 | Corden Pharma International GmbH | A new method for producing nebivolol hydrochloride of high purity |
| DE102014107132A1 (de) | 2014-05-20 | 2015-11-26 | Corden Pharma International Gmbh | Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind |
| JP6847095B2 (ja) | 2015-05-19 | 2021-03-24 | チョーチアン オウスン ファーマシューティカル カンパニー リミテッド | ネビボロールの合成方法及びその中間化合物 |
| CN105085499B (zh) * | 2015-08-07 | 2018-09-25 | 上海现代制药海门有限公司 | 盐酸奈必洛尔中间体混合物的结晶分离方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1054655A (sv) * | 1964-01-24 | |||
| US4313955A (en) * | 1980-10-14 | 1982-02-02 | Ciba-Geigy Corporation | 1,5-Bis(1,4-benzodioxin-2-yl)-3-azapentane-1,5-diols |
| GB8418472D0 (en) * | 1984-07-19 | 1984-08-22 | Beecham Group Plc | Compounds |
-
1984
- 1984-11-19 CA CA000468108A patent/CA1337429C/en not_active Expired - Fee Related
- 1984-11-21 PL PL1984250524A patent/PL146342B1/pl unknown
- 1984-11-22 DE DE8484201693T patent/DE3476388D1/de not_active Expired
- 1984-11-22 EP EP84201693A patent/EP0145067B1/en not_active Expired
- 1984-11-22 AT AT84201693T patent/ATE40361T1/de not_active IP Right Cessation
- 1984-11-26 KR KR1019840007404A patent/KR870000923B1/ko not_active IP Right Cessation
- 1984-11-29 GR GR81098A patent/GR81098B/el unknown
- 1984-11-29 NZ NZ210388A patent/NZ210388A/en unknown
- 1984-11-30 JP JP59252038A patent/JPS60132977A/ja active Granted
- 1984-12-02 DZ DZ847346A patent/DZ712A1/fr active
- 1984-12-03 AR AR84298819A patent/AR241414A1/es active
- 1984-12-03 RO RO116496A patent/RO91184B/ro unknown
- 1984-12-03 IL IL73706A patent/IL73706A/xx not_active IP Right Cessation
- 1984-12-03 DD DD84270216A patent/DD235453A5/de not_active IP Right Cessation
- 1984-12-04 NO NO844845A patent/NO169839C/no not_active IP Right Cessation
- 1984-12-04 ZW ZW197/84A patent/ZW19784A1/xx unknown
- 1984-12-04 DK DK577084A patent/DK165112C/da not_active IP Right Cessation
- 1984-12-04 ES ES538256A patent/ES538256A0/es active Granted
- 1984-12-04 PT PT79609A patent/PT79609B/pt unknown
- 1984-12-04 PH PH31525A patent/PH22432A/en unknown
- 1984-12-04 SU SU843826501A patent/SU1428199A3/ru active
- 1984-12-04 FI FI844777A patent/FI82460C/sv active IP Right Grant
- 1984-12-04 HU HU844482A patent/HU202219B/hu unknown
- 1984-12-04 IE IE3103/84A patent/IE57831B1/en not_active IP Right Cessation
- 1984-12-04 BG BG067765A patent/BG43866A3/xx unknown
- 1984-12-04 ZA ZA849445A patent/ZA849445B/xx unknown
- 1984-12-04 MA MA20516A patent/MA20292A1/fr unknown
- 1984-12-04 CS CS849320A patent/CS250242B2/cs unknown
- 1984-12-05 AU AU36326/84A patent/AU573658B2/en not_active Expired
-
1991
- 1991-06-18 SG SG47091A patent/SG47091G/en unknown
- 1991-07-11 HK HK527/91A patent/HK52791A/xx not_active IP Right Cessation
-
1992
- 1992-01-31 DK DK011892A patent/DK165321C/da not_active IP Right Cessation
- 1992-04-03 CY CY1609A patent/CY1609A/xx unknown
-
2004
- 2004-11-26 NO NO2004007C patent/NO2004007I2/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI82460B (fi) | Foerfarande foer framstaellning av nya, -adrenergiskt blockerande 2,2'-iminobisetanolderivat. | |
| US4654362A (en) | Derivatives of 2,2'-iminobisethanol | |
| JP5416740B2 (ja) | てんかんおよび関連疾患を治療するためのスルファメートおよびスルファミド誘導体 | |
| SK280166B6 (sk) | [(benzodioxán, benzofurán alebobenzopyrán)alkylami | |
| US4251537A (en) | Hypotensive 3,4-dihydro-2,2-dimethyl-4-amino-2H-benzo[b]pyran-3-ols | |
| US5403842A (en) | Benzopyran and benzothiopyran derivatives | |
| FI76331B (fi) | Foerfarande foer framstaellning av terapeutiskt aktiva substituerade 4-aminometylenkromaner och kromener. | |
| HU179433B (en) | Process for preparing new carbazolyl-/4/-oxy-propanolamine derivatives and pharmaceutical compositions containing thereof | |
| JP2008503488A (ja) | てんかんおよび関連疾患を治療するためのスルファメートおよびスルファミド誘導体 | |
| IL110689A (en) | Vasodilators containing aryloxylalkyldiamine, certain new compounds and their preparation | |
| WO2009120192A2 (en) | Process for the preparation of benzo-fused heteroaryl derivatives | |
| JP2003503492A (ja) | メラトニン作用剤としての複素環式アミノピロリジン誘導体 | |
| AU741753B2 (en) | Substituted heterocyclic compounds, method for preparing and compositions containing same | |
| US5166367A (en) | Antipsychotic benzodioxan derivatives | |
| US5439909A (en) | New substituted benzodioxins | |
| EP2271635A1 (en) | Modulators of dopamine neurotransmission | |
| US5189171A (en) | Antipsychotic benzodioxan derivatives | |
| CA2387727C (en) | Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them | |
| JPS6054317B2 (ja) | 新規ベンゾピラン誘導体 | |
| WO2001036428A1 (en) | Silylated heterocyclic compounds | |
| CA2395984A1 (en) | Novel heteroaryl derivatives, their preparation and use | |
| JPS6031829B2 (ja) | アミノアルコ−ル誘導体の製造法 | |
| US5273994A (en) | 3-aminochroman compounds | |
| WO2000000489A2 (en) | 6-(4-arylalkylpiperazin-1-yl)benzodioxane and 6-(4-arylalkylpiperazin-1-yl)chromane derivatives: dopamine receptor subtype specific ligands | |
| US20010005753A1 (en) | 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ND | Supplementary protection certificate (spc) granted | ||
| SPCG | Supplementary protection certificate granted |
Spc suppl protection certif: L79 Extension date: 20091204 |
|
| FG | Patent granted |
Owner name: JANSSEN PHARMACEUTICA N.V. |